F-Star Therapeutics Limited
F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer. Through the application of its highly efficient Modular Antibody Technology™ platform, F-star is the only biotechnology company able to create bispecific antibodies, where the second binding site is in the constant Fc region of an antibody, offering unprecedented ease in the discovery, development and manufacturing of bispecific antibody products. The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including, AbbVie, Bristol-Myers Squibb, Merck Serono and Boehringer Ingelheim.. . For more information visit https://www.f-star.com